Control prenatal apropiado: la mejor manera de prevenir la pre-eclampsia en los países andinos by Jaramillo, Patricio López et al.
226
Colombia Médica                  Vol. 40 Nº 2, 2009 (Abril-Junio)
1. Director of  Research, Fundación Cardiovascular de Colombia y de Investigaciones de la Facultad de Medicina, Univer-
sidad de Santander (UDES), Bucaramanga, Colombia. e-mail: joselopez@fcv.org
2. Coordinator of Research, Fundación Cardiovascular de Colombia, Bucaramanga, Colombia. e-mail: ronaldgarcia@fcv.org
e-mail: silviaruiz@fcv.org
3. Assistant of Research, Fundación Cardiovascular de Colombia, Bucaramanga, Colombia. e-mail: laurareyes@fcv.org
Received for publication March 8, 2009       Accepted for publication April 14, 2009
© 2009 Universidad del Valle, Facultad de Salud                                              Colomb Med. 2009; 40: 226-30
The main cause of maternal mortality in Colombia is
preeclampsia (PE). It causes 42% of the maternal
demises and increases the perinatal mortality by five
fold. It is even a bigger problem if it is considered that
maternal mortality in Colombia is ten times higher than
in United States of America1. In spite of its impact on
public health PE’s aetiology and physiopathology remain
unknown. In this paper it is postulated that PE is a
disorder due to multiple causes, and that nutritional,
socioeconomic, genetic and environmental factors might
lead to an endothelial function alteration characterized
by a modification in the production of vasoactive
substances, especially nitric oxide (NO), prostacyclin,
and pro oxidizing free radicals2. Furthermore, this article
proposes that the weight of  these risks factors varies
depending on the level of socioeconomic development
reached by a given society3.
Relevant epidemiological observations to prevent
PE. PE complicates about 6% to 8% of pregnancies;
however, noticeable regional differences exist in its
incidence due to the greater presence of certain risk
factors in developing societies4. Nutritional factors like
the low intake of calcium1, antioxidizing vitamins5 and
essential fatty acids6 are considered elements
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SUMMARY
The main cause of maternal mortality in Colombia is preeclampsia; even though it is a major public health problem its etiology
and physiopathology remain unknown. However it is believed that endothelial dysfunction plays a central role in the
development of this disease. Many clinical trials have been carried out to demonstrate the effect of certain interventions to
prevent preeclampsia and improve pregnancy outcomes. Our hypothesis is that the reduction of preeclampsia risk could be
achieved through an appropriate health system that would provide an opportune and effective prenatal care to pregnant women
allowing early diagnosis and treatment of frequent nutritional and health related problems.
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RESUMEN
La primera causa de mortalidad materna en Colombia es la pre-eclampsia; pero aunque es un problema de salud pública su
etiología y fisiopatología no se han esclarecido completamente. Sin embargo, se cree que la disfunción endotelial juega un papel
importante en el desarrollo de la enfermedad. Se han llevado a cabo múltiples ensayos clínicos para demostrar el efecto de ciertas
intervenciones a fin de prevenir la pre-eclampsia y mejorar los resultados de estos embarazos. Nuestra hipótesis consiste en
que la reducción del riesgo de desarrollar pre-eclampsia se puede obtener mediante un sistema de salud apropiado que brinde
a la madre un control prenatal efectivo y oportuno y permita el diagnóstico temprano y el tratamiento de sus problemas de salud
y nutricionales.
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contributing to an increasing risk of developing PE. In
addition, the findings of a large scale population study
carried out in Colombia led the present authors to
propose that chronic subclinical infections are the main
risk factor for PE in this country7, proposal which it has
been recently supported by demonstrating that
inflammation associated to oral, vaginal, and urinary
infections precedes the PE development8,9. These
observations are important since they have served as a
support for the realization of studies directed to prevent
the disease.
PE preventing strategies. The lack of an adequate
knowledge of PE’s physiopathology has determined
that many of the strategies used to prevent it are based
on observational or anecdotic facts or in studies
performed with women at high risk of developing the
disease. Many non pharmacological strategies have
been used to prevent PE, especially those related with
nutritional restrictions or nutritional supplements, and
rest in bed10,11. In the next section those in which greater
evidences of a beneficial effect exists will be reviewed.
Calcium supplements. Three pioneer clinical trials
carried out by López-Jaramillo et al.12-14 with 408
Andean Ecuadorian primigravid women showed that
calcium supplement of 2 g daily in this population with
history of a low intake of this mineral was useful to
prevent the development of pregnancy induced
hypertension and PE. The Cochrane library most recent
metaanalysis15 which included 11 randomized, double-
blind placebo-controlled clinical trials reported that
calcium supplementation is associated with a reduction
of the risk of increased arterial pressure during pregnancy
(11 clinical trials, 14,946 women: relative risk (RR) 0.70,
95% CI 0.57-0.86). There also was a reduction in the
risk of PE associated to calcium supplementation (12
clinical trials, 15,206 women RR 0.48, 95% CI: 0.33-
0.69), specially in those who had a low basal intake of
calcium (7 clinical trials, 10,154 women: RR 0.36, 95%
CI: 0.18-0.70) and in those considered at high risk (5
clinical trials, 587 women: RR 0.22, 95% CI: 0.12-0.42).
The authors of this important metaanalysis concluded
that calcium supplementation appears to almost halve
the risk of PE, and to reduce the occurrence of a
composite outcome of death or «serious morbidity».
Villar and the clinical trial group of calcium
supplementation for the prevention of PE of the World
Health Organization (WHO)16, included 8,325 women
with a low intake of calcium (less than 600 mg per day)
and less than 20 weeks pregnant; of them, 4,157 received
1.5 g of calcium per day and 4,168 received placebo.
This calcium supplementation was associated with a
small non statistically significant reduction of PE (4.1%
vs. 4.5%). However, severe pregnancy-induced hyper-
tension (RR 0.71, 95% CI: 0.61-0.62) and eclampsia
(RR 0.68, 95% CI: 0.48-0.97) were significantly lower
in the supplemented group. Besides, a reduction in the
rate of complications of severe PE was observed (RR
0.76, with a 95% CI: 0.66-0.89). Severe maternal
morbidity and the mortality rate (RR 0.80, 95% CI: 0.70-
0.91), and neonatal mortality rate (RR 0.70, 95% CI:
0.56-0.88) were also significantly lower in the calcium
supplemented group. This important clinical trial realized
in a low calcium intake population demonstrated that
although 1.5 g of calcium supplementation per day did
not statistically diminish the total incidence of PE, it
significantly diminished the risk of the most serious PE
complications, including maternal death, preterm birth
and maternal and neonatal morbidity. Based on these
results, the authors analyzed the practical implications
of calcium supplementation in population with a low
intake of this mineral and concluded that 125 women
should be treated to prevent a severe complication of
PE, and 167 should be treated to prevent a very premature
preterm birth. These numbers are reduced to 45 and 71,
respectively if the pregnant women are less than 20
years old. Finally, they assure that it would be necessary
to supplement 100 women to prevent severe maternal
morbidity and one death event, and that it would be
necessary that 250 pregnant women receive calcium
supplementation to prevent one neonatal death. The
WHO group affirms that «acute and long term
consequences of these poor outcomes; combined with
the socioeconomic limitations justified the calcium
supplementation».
Recently, Hofmeyr et al.17 proposed that the
investigation about this subject should be redirected
from clinical trials to communitarian interventions with
calcium supplementation. This proposal, consistent with
López-Jaramillo & de Félix’s18, considers calcium
supplementation as a preventive nutritional measure
directed at overcoming a socioeconomic problem, which
frequently impedes the access to dairy products to poor
women in Colombian society during their pregnancy,
and that it should not be prescribed to women with an
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adequate consumption of the mineral. Pregnancy is a
period during which women need an extra calcium
consumption to guarantee a positive balance of the
mineral to compensate the great demand of calcium
necessary for fetal bone mineralization19.
Other dietary supplementations: Antioxidants.
There are multiple clinical trials, in which a dietary
supplementation including either magnesium, fish oil or
C and E vitamins was administered, but results have
been contradictory. Indeed, the most recent metaanalysis
of the Cochrane library20 determined that there was no
significant difference between antioxidant and control
groups in the RR of PE (RR 0.73, 95% CI 0.51 to 1.06;
nine trials, 5,446 women) or any other primary outcome:
severe PE (RR 1.25, 95% CI 0.89 to 1.76; two trials,
2,495 women), preterm birth (before 37 weeks) (RR
1.10, 95% CI 0.99 to 1.22; five trials, 5,198 women),
small-for-gestational-age infants (RR 0.83, 95% CI
0.62 to 1.11; five trials, 5,271 babies) or any baby death
(RR 1.12, 95% CI 0.81 to 1.53; four trials, 5,144 babies).
The authors concluded that the evidence from this
review does not support routine antioxidant supplemen-
tation during pregnancy to reduce the risk of PE and/or
other serious complications in pregnancy.
On the other hand, the results of a clinical trial
including 2,951 pregnant women were recently
published21 demonstrating that multivitamins and folic
acid supplementation were associated with an increase
in serum folate, a decrease of plasmatic homocysteine
and a risk reduction of PE (RR 0.37, 95% CI: 0.18-0.75).
More studies are necessary to confirm this persuasive
interaction in view of the proposal that a change in the
oxidant/antioxidant balance is one of the mechanisms
leading to an endothelial function alteration which
characterizes PE22. Since many serious and well
designed clinical trials are being carried out, we should
wait for their results before recommending the routine
use of antioxidant vitamin supplements during pregnancy
to prevent PE.
PHARMACOLOGICAL INTERVENTIONS
Low aspirin doses. A recent review of the Cochrane
library23 examined the results of 59 clinical trials which
included 37,560 pregnant women and that were directed
to evaluate the effectiveness and safety of low aspirin
doses to diminish the risk of developing PE. A reduction
of 17% in the risk of PE associated with the use of
antiplatelets doses was observed [(46 clinical trials,
32,891 women, RR 0.83, 95% CI: 0.77-0.89), number
needed to treat (NNT) 72 (52,119)]. Despite the fact
that there were no statistical differences in the RR
based on maternal risk, a significant increase in the
reduction of the absolute risk of developing PE was
observed in women at high risk compared with those at
moderate risk. The authors concluded that the
administration of low aspirin doses has moderate benefits
in the prevention of PE and proposed that more
information is necessary to determine which women
can benefit from this intervention, when the treatment
should be initiated, and which dose must be used. From
a practical point of view, the authors leave the decision
of its use to both the pregnant woman and her doctor.
Since it is a small reduction in the risk of developing PE,
a large number of women need to be treated to prevent
only one adverse outcome, which seems little practical,
although even this small reduction could be useful from
a public health perspective.
Treatment of vaginal, periodontal and urinary
infections. Some studies have shown that urinary and
vaginal infections can cause PE7,24-26. Furthermore, it is
well known that the incidence of asymptomatic
bacteriuria is three times higher in women with PE, and
that urinary infection is a strong risk factor for PE25,26.
Recently Herrera et al.9 demonstrated an association
between PE, C-reactive protein concentration and
periodontitis.
Many studies have shown that the identification and
treatment of bacterial vaginosis and urinary infection
reduces the presentation of preterm delivery, and
premature rupture of fetal membranes27,28, and Herrera
et al.7 demonstrated in Colombian women that early
detection (14-20 weeks of gestational age) and opportune
treatment of vaginal and urinary infections reduced the
incidence of PE by 64.7%.
Since the realization of double blind, placebo-
controlled clinical trials to evaluate the effect of the
treatment of subclinical infection are not ethically
acceptable, community work evaluating the impact of
early diagnoses of subclinical infections and their
adequate treatment is an urgent need in countries where
vaginal, oral, and urinary infections can affect up to 50%
of the expectant mothers. Besides, it has been
demonstrated that low grade inflammation associated to
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endothelial dysfunction, precedes the clinical mani-
festation of PE, and that the treatment of infections
recovers the endothelial function8,29.
OTHER  PHARMACOLOGICAL
INTERVENTIONS
It has been reported that the use of diuretics does not
have any effect on PE prevention or its complications30,
and that their use is not recommended considering the
high levels of adverse events found a recent metaanalysis
(1,836 women). Regarding the use of exogenous donors
of NO or of the substratum for its synthesis (L-arginine)
to prevent PE, the metaanalysis31 of six clinical trials that
included 310 women showed that the data available are
insufficient to reach appropriate conclusions about
whether exogenous donors of NO or its substratum are
useful to prevent PE.
HYPOTHESIS
The hypothesis can be summarized as follows:
preeclampsia is the result of a combination of economical,
psychological, social, nutritional, environmental and
genetic factors that culminate in an alteration in the
production of the free radicals NO, O2- and ONOO-.
The specific weight of each factor differs between
developed and developing countries2. Poor women from
developing countries like Colombia and Ecuador are the
most exposed to these risk factors, which explains the
high incidence of the disease, converting it into the main
cause of maternal mortality.
We have proposed an integral model which pretends
to include and relate the different factors that could
participate in the reduction of PE incidence in our
countries (Figure 1). The right interpretation of this
model allows us to understand that the most economical,
effective and universal way to prevent PE is a social
system that guarantees an adequate nutrition of the
pregnant women and the access to an adequate system
of prenatal care which would include the administration
of prenatal tablets containing among other components
vitamins C and E and minerals such as calcium, which
would compensate for the extra demand of nutrients
that are taken from the mother by the foetus for its
organic development. Moreover, an adequate prenatal
control not only allows the diagnosis and early treatment
of subclinical urinary, oral and vaginal infections, but
also the identification and correction of bad nutritional
practices that are expressed in an excessive weight gain
and biochemical alterations of the lipid profile and
carbohydrates. In populations with marked deficiencies
of some nutrients, as it is the case of calcium in Latin-
American women, or antioxidant vitamins in Caucasian
women, the administration of these supplements is
necessary.
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